All In Biotech

Drug Trial Radar · NCT03066219

Safety and Efficacy of BRM421 for Dry Eye Syndrome

A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of BRM421 Ophthalmic Solution in Subjects With Dry Eye Using a Controlled Adverse Environment (CAE®) Model

Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 157 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

157

Actual

Start

Feb 7, 2017

Primary completion

May 20, 2017

Study completion Jun 28, 2017

Sponsor

Lead sponsor
BRIM Biotechnology Inc.Industry
Sponsor type
Industry
First posted
Feb 28, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to compare the safety and efficacy of BRM421 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.

Conditions

  • Dry Eye Syndrome

Interventions

  • BRM421Drug

    0.03%(w/v) BRIM421 ophthalmic solution

  • PlaceboDrug

    vehicle ophthalmic drops

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sign: Corneal Fluorescein Staining ScoreTime frame: change from baseline to week 4
  2. Symptom: Ocular Discomfort ScoreTime frame: change from baseline to week 4

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Central Maine Eye Care

    Lewiston, Maine

  • Andover Eye Associates

    Andover, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.